![Dermaxon receives grant from the National Institute of Neurological Disorders and Stroke](https://dermaxon.com/wp-content/uploads/2020/01/lab-chemistry.jpg)
![Dermaxon receives grant from the National Institute of Neurological Disorders and Stroke](https://dermaxon.com/wp-content/uploads/2020/01/lab-chemistry.jpg)
![DermaXon LLC awarded grant for continued development of DX308 drug candidate for the treatment of Ichthyosis](https://dermaxon.com/wp-content/uploads/2020/01/lab-worker-beaker.jpg)
DermaXon LLC awarded grant for continued development of DX308 drug candidate for the treatment of Ichthyosis
MiSSOULA, Montana, Nov. 20, 2018 – DermaXon was been awarded a research grant from The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to further research treatment options for Ichthyosis.
Characterization of CYP26B1-selective Inhibitor, DX314, as a Potential Therapeutic for Keratinization Disorders.
Background: Retinoid-based therapies are commonly used in the treatment of disorders of keratinization and other skin disorders but can result in non-specific effects and adverse reactions. Use of retinoic acid metabolism blocking agents (RAMBAs) such as DX308 may...![Dermaxon receives grant from the National Institute of Neurological Disorders and Stroke](https://dermaxon.com/wp-content/uploads/2020/01/lab-worker-results.jpg)